BRIEF-GSK receives positive EMA opinion for melanoma drug Mekinist

April 25 Fri Apr 25, 2014 10:51am EDT

Related Topics

April 25 (Reuters) - Glaxosmithkline Plc

* GSK receives positive CHMP opinion for Mekinist (Trametinib) in metastatic melanoma with a braf v600 mutation

* A final decision by EC is anticipated during Q2 of 2014

* CHMP recommendation based on randomised open label phase III study in 322 patients For the full story, click on Further company coverage:

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article